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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Bakgrund 
Patienter som söker akutmottagningen på grund av bröstsmärta utgör 5-10% av alla akuta 
besök årligen i Europa och USA [1,2]. Bröstsmärta kan vara ett symtom på hjärtinfarkt som 
kräver omedelbar behandling men 80-85% av alla patienter med bröstsmärta diagnostiseras 
med helt ofarliga tillstånd. Det är därför oerhört viktigt att snabbt och säkert kunna avgöra 
vilka patienter som behöver läggas in på sjukhus för undersökning eller kan gå hem direkt 
från akutmottagningen. För att undersöka om en patient har hjärtinfarkt, görs en klinisk 
undersökning, EKG tas samt blodprover för att mäta biomarkörer i blodet [3].  
Olika biomarkörer har använts sedan 1950-talet för att bekräfta eller utesluta 
hjärtmuskelskada. På 1990-talet introducerades troponin som den mest hjärtspecifika 
biomarkören hittills. Riktlinjer har rekommenderat att man ska ta upprepade 
blodprovsmätningar av troponin efter symtomdebut innan man kan utesluta hjärtinfarkt, vilket 
ledde till en rädsla för ökade inläggningar på sjukhus för observation [3]. Endast ca 15-20% av 
patienter som läggs in på sjukhus för bröstsmärta, får slutligen diagnosen hjärtinfarkt. 
Troponinmetoden har utvecklats och nyligen introducerades så kallat högkänsligt troponin 
(hs-cTnT) som är känsligare och som kan mäta hjärtmuskelskada i blodet flera timmar 
tidigare än äldre troponinmetoder [4].  
 
Denna avhandling baseras på fyra studier som utvärderar högkänsligt troponin som 
analysmetod på akutmottagningen sedan introduktionen i kliniken, dess effekter på 
handläggning av patienter med bröstsmärta på akutmottagningen samt resursutnyttjande på 
sjukhus.  
 
Metod och Resultat 
I Studie I utvärderade vi om ett första omätbart värde på hs-cTnT och ett normalt EKG 
kunde utesluta hjärtinfarkt direkt på akutmottagningen. Vi inkluderade 14,636 patienter som 
sökte med bröstsmärta på akutmottagningen på Karolinska Universitetssjukhuset under två 
år. Resultaten visade att risken för att utveckla hjärtinfarkt var minimal om EKG var normalt 
och ett första högkänsligt troponinvärde var omätbart.  
 
I Studie II undersökte vi om de patienter som skickats hem från akuten i Studie I återkom i 
högre grad än om de hade lagts in på sjukhus. Efter att vi hade exkluderat de patienter som 
hade hjärtinfarkt vid besöket, inkluderade vi resterande 13,046 patienter som sökt 
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akutmottagningen på grund av bröstsmärta på Karolinska Universitetssjukhuset under två år. 
För patienter med omätbart högkänsligt troponin som lagts in på sjukhus jämfört med de som 
gått hem direkt från akutmottagningen fann vi en 24% ökad risk för återbesök till sjukhus 
samt en 3 gånger så hög risk att genomgå kranskärlsröntgen och kranskärlsingrepp. 
 
Studie III studerade trender i inläggning på sjukhus efter introduktionen av högkänsligt 
troponin. Studien innefattade 15,472 patienter som sökt akutmottagningen på grund av 
bröstsmärta på Karolinska Universitetssjukhuset i Huddinge under 4 år. Resultaten visade att 
inläggningar på sjukhus på grund av bröstsmärta minskat med 36% sedan högkänsligt troponin 
införts som analysmetod.  
 
Studie IV utvärderade överlevnad och resursutnyttjande för 31,904 patienter som sökt på 
grund av bröstsmärta på akutmottagningen på Karolinska Universitetssjukhuset under 5 år. 
De första 3 åren när högkänsligt troponin introducerades jämfördes med de 2 föregående 
åren när konventionellt troponin användes som analysmetod. Resultaten visade en liten 
minskning i överlevnad samt fler genomförda kranskärlsröntgen och kranskärlsingrepp 
sedan högkänsligt troponin introducerats. 
 
Slutsatser 
Studie I: Patienter som söker på grund av bröstsmärta och har ett första högkänsligt 
troponinvärde som är omätbart samt ett normalt EKG har en minimal risk att drabbas av 
hjärtinfarkt och kan säkert skickas hem från akutmottagningen.  
 
Studie II: När patienter som söker akut på grund av bröstsmärta och har ett omätbart 
högkänsligt troponinvärde läggs in på sjukhus istället för att skickas hem, ökar risken för 
återbesök till akuten, upprepade inläggningar på sjukhus, kranskärlsröntgen och 
kranskärlsingrepp.  
 
Studie III: Inläggningar på sjukhus på grund av bröstsmärta minskade med 36% under de 
första 4 åren efter att högkänsligt troponin införts på akutmottagningen.  
  
Studie IV: Efter introduktionen av högkänsligt troponin observerades en liten minskning i 
överlevnad samt en ökning av resursutnyttjande. Resultaten bör tolkas med försiktighet.  
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ABSTRACT 
 
Background   
Patients presenting with chest pain in the emergency department (ED) may have myocardial infarction 
(MI) requiring immediate treatment. High-sensitivity cardiac troponin T (hs-cTnT) was recently 
introduced as a biomarker that aids in determining whether the patient requires hospital admission or can 
be safely discharged home. The aim of this thesis was to evaluate the implementation of hs-cTnT in the 
ED, with respect to hospital admission, resource utilization and patient outcomes. 
 
Methods and Results 
Two separate datasets were created by combining administrative information from the ED at 
Karolinska University Hospital with laboratory data and linking several national health care registers 
through the National Board of Health and Welfare. The first dataset was used for Studies I and II, 
while the second dataset was used for Studies III and IV. Cox regression was used to calculate hazard 
ratios (HRs) with 95% confidence intervals (CIs). 
 
Study I: In total, 14,636 patients with chest pain who presented to the EDs at Karolinska University 
Hospital, Solna and Huddinge, during 2011 and 2012 were included to evaluate whether a first 
undetectable (<5 ng/L) hs-cTnT level and an electrocardiogram (ECG) without signs of ischaemia 
could be used to safely rule out MI in the ED. We identified 15 patients with an undetectable hs-cTnT 
level and non-ischaemic ECG who were diagnosed with MI within 30 days. The negative predictive 
value for MI using this strategy was 99.8%, and for death 100%.  
 
Study II: We included 13,046 patients with chest pain who visited the ED at Karolinska University 
Hospital, Solna and Huddinge, during 2011 and 2012. We calculated HRs at different hs-cTnT levels 
for the risk of revisits to the ED, readmissions to hospital and resource utilization in terms of whether 
the patient was discharged or admitted. In patients with a hs-cTnT level of <5 ng/L who were 
admitted to the hospital compared with discharged home, we observed a 24% increased risk (adjusted 
HR 1.24, 95% CI 1.05–1.46) of revisiting the ED within 30 days and a three-fold increased risk of 
coronary angiography or revascularization during follow-up.   
 
Study III: We evaluated trends in admission rates among 15,472 patients with chest pain who presented 
to the ED at Karolinska University Hospital, Huddinge from 2011 to 2014. Proportions of admitted 
patients were calculated using each year of the study period (2012, 2013 and 2014) as exposure with 
year 2011 as reference. We found a 36% relative reduction in hospital admissions. All-cause mortality 
increased (adjusted HR 1.51, 95% CI 1.18–1.92), but for non-cardiovascular causes only. Coronary 
angiography significantly increased, but revascularizations remained stable. 
 
Study IV: Survival and resource utilization in 31,904 patients with chest pain were compared during 
the initial 3 years (2011-2013) when the hs-cTnT assay was implemented to the preceding 2 years 
(2009-2010) when the conventional troponin (cTnT) assay was in use at Karolinska University 
Hospital, Solna and Huddinge. Patients who were tested with hs-cTnT had a 15% increase in all-cause 
mortality (adjusted HR 1.15, 95% CI 1.02–1.29), 13% increase in coronary angiography (adjusted HR 
1.13, 95% CI 1.00–1.28) and 18% increase in revascularizations (adjusted HR 1.18, 95% CI 1.01–
1.37). 
 
Conclusions  
[I] Patients presenting with chest pain, a first undetectable hs-cTnT level and a normal ECG may be 
safely discharged from the ED because the risk of MI or death is minimal. [II] When patients with 
chest pain and an undetectable hs-cTnT level are admitted to the hospital instead of discharged home, 
they have an increased risk of revisits to the ED, recurrent hospital stays, coronary angiography and 
revascularization. [III] Admissions for chest pain were reduced by 36% during the first 4 years of hs-
cTnT use. All-cause mortality increased, but for non-cardiovascular causes only. [IV] After the 
introduction of hs-cTnT testing in the ED, an increase in mortality, coronary angiography and 
revascularizations was observed.  
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INTRODUCTION 
 
Patients presenting with chest pain account for 5% to 10% of all visits to the emergency 
department (ED) [1,2]. Chest pain may be a symptom of myocardial infarction (MI) 
requiring immediate treatment; therefore, these patients have often been admitted to 
hospital for observation. But only 10% to 20% of patients who are admitted to hospital 
because of chest pain, are diagnosed with MI; most patients are diagnosed with non-
cardiac conditions [3]. Rapid diagnosis of the cause of chest pain is important to 
determine whether the patient requires admission to hospital or can be safely discharged 
home from the ED. The diagnostic tools used to rule out MI are clinical assessment, an 
electrocardiogram (ECG), and measurement of cardiac biomarkers, commonly troponin. 
Guidelines have recommended serial measurements of to rule out MI, which often 
means that patients with chest pain must be admitted to hospital [3].  
High-sensitivity cardiac troponin T (hs-cTnT) was recently implemented in the clinical 
setting. The biomarker has the ability to detect myocardial damage in the blood several 
hours earlier than previous biomarkers [4]. Introduction of hs-cTnT raised the question 
of whether hospital admission for repeated measurements of troponin is still necessary 
[5,6]. The ability to safely and rapidly rule out MI, without serial testing or observation, 
may lead to reduced hospital admissions and downstream investigations and improved 
outcomes [7].  
 
The aim of this thesis was to study the clinical impact of implementing hs-cTnT in the 
ED with respect to hospital admissions, resource utilization and patient outcomes.  
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BACKGROUND 
 
CHEST PAIN 
A key problem in the ED is how to rapidly diagnose patients with MI among all 
patients with chest pain. Approximately 5% of all patients visiting the ED have chest 
pain as the main complaint, making it the second most common cause for a visit to 
the ED; however only 5% of all patients presenting with chest pain are actually  
diagnosed with MI [1].  
 
The first purpose of evaluation of chest pain is to determine whether it is of cardiac 
(ischaemic) or non-cardiac origin. The most prominent symptoms (also known as 
"typical" symptoms) of cardiac ischaemia are retrosternal pain and/or pressure with a 
radiation to the left arm or jaw that may be persistent for a couple of minutes or 
occur intermittently [8]. However, radiation to the left arm does not increase the 
probability of MI [9]. Diaphoresis, nausea or vomiting, back pain, epigastric 
discomfort, or dyspnoea may also be symptoms of myocardial ischaemia [3].  
 
There is also a high prevalence of symptoms (also known as "atypical" symptoms) 
that do not primarily raise suspicions of cardiac origin, such as pleuritic knife-like 
pain and tenderness upon palpation of the thorax. The onset is often random and 
unrelated to physical activity and can last for seconds, minutes, hours, or all day. 
Afferent nerve fibres from the heart, lungs, oesophagus, and great vessels carry 
information to the same thoracic autonomic ganglia. Because of fibre overlap in the 
dorsal ganglia, a pain stimulus from any of these organs may be experienced in the 
thoracic region and hence give rise to a number of cardiac and non-cardiac causes of 
chest pain [10]. However, even patients with "atypical" symptoms may have 
myocardial ischaemia, which complicates the diagnostic process [3]. Studies have 
investigated the clinical value of pain severity, facial expressions and symptoms in 
different ethnic groups during potential MI, but limited diagnostic value for MI has 
been found [11-13].  
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Possible differences in the presentation of symptoms of MI between men and women 
have also been thoroughly investigated [8,14-18]. Guidelines state that "atypical" 
symptoms of MI are more common in women than men [8]. An important clinical 
question is whether using sex-specific characteristics of chest pain can improve early 
diagnosis of MI. Some studies have reported minimal differences in symptoms suggestive 
of MI between women (more often nausea or jaw pain) and men [14-16]. However, these 
differences are so small that implementation of sex-specific characteristics is not 
clinically applicable. Some studies have observed no differences in symptom presentation 
between the two sexes [17,18].  
 
Apart from myocardial ischaemia, other potentially life-threatening conditions may 
also be characterized by an onset of chest pain, such as pulmonary embolism or 
pneumothorax, which presents with an immediate onset of dyspnoea and thoracic 
aortic dissection, which presents with high-intensity chest pain [19]. These conditions 
are rare in patients presenting with chest pain but need to be assessed immediately in 
the ED. 
 
MYOCARDIAL INFARCTION 
Incidence of MI 
The incidence of MI in Sweden during the last 30 years has decreased markedly, as 
depicted in FIGURE 1 [20]. 
 
FIGURE 1. Incidence of MI per 100.000 individuals for both sexes, age 20-85 years, during 1987-
2015 in Sweden.  
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Classification based on mechanism 
MI is commonly categorized according to the underlying mechanism, as depicted in 
TABLE 1 [3]. Type 1 MI constitutes approximately 88% of all MIs in admitted 
patients according to a recent study [21]. Fewer patients are diagnosed with type 2 
MI, approximately 7% of all MIs, and form a more heterogeneous group. Type 3 MI 
is rare, constituting approximately 3% of all MIs [22]. 
 
TABLE 1. Classification of MI. 
Type Mechanism 
1 Spontaneous MI caused by atherosclerotic plaque rupture. A thrombus will 
occlude one or more of the coronary arteries leading to decreased myocardial 
blood flow and ischaemia. 
2 MI secondary to myocardial oxygen supply and demand imbalance, caused by a 
condition other than atherosclerotic disease, such as sepsis, arrythmias, 
respiratory failure, hypotension or hypertension.  
3 MI caused by presumed myocardial ischaemia leading to cardiac death before 
biomarkers is obtained. 
4a MI related to coronary angiography or PCI 
4b MI related to stent thrombus 
5 MI associated with CABG 
Abbreviations: myocardial infarction (MI); percutaneous coronary intervention (PCI); coronary  
artery bypass grafting (CABG). 
 
 
Classification based on ECG  
The diagnosis of MI is determined by patient symptoms, ECG-findings, and a rise 
and/or fall of a biomarker, commonly troponin, with one value above the 99th 
percentile of the upper reference limit [3]. Upon arrival to the ED, a patient 
presenting with chest pain immediately undergoes ECG recording. A normal ECG-
complex is depicted in FIGURE 2. The ST-segment represents the interval between 
ventricular depolarization and the start of repolarization [3]. When an atherosclerotic 
plaque in the artery wall ruptures, it may lead to total artery occlusion, causing 
ischaemia in the myocardium supplied by that artery. The cardiac wall will undergo 
early repolarization which elevates the ST-segment, as shown in FIGURE 2 [3]. Such 
patients have developed ST-segment elevation MI (STEMI) and should be rapidly 
reperfused with coronary angiography and primary PCI at a PCI-capable hospital, or 
else undergo thrombolysis [23]. 
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FIGURE 2. The normal ECG complex and ECG during STEMI and NSTEMI. Image reproduced 
with permission from the publisher. 
 
The ECG is a cornerstone in the diagnosis of STEMI, while ECG findings are 
normal in more than one-third of all patients with non-ST-segment elevation MI 
(NSTEMI). During NSTEMI, the ECG may show ST-segment depression or T-wave 
changes. In the case of partial coronary artery occlusion, an earlier onset of 
subendocardial repolarization will occur leading to a depression of the ST-segment. 
A reverse electrophysiological wave will result in an inverted T wave, as depicted in 
FIGURE 2 [8]. During NSTEMI, the primary goal is to stabilize the patient using 
nitrates and morphine for the chest pain, beta-blockers, platelet inhibitors, and 
anticoagulants. Thereafter, the physician decides on conservative therapy or invasive 
methods, such as coronary angiography with the possibility of revascularization. These 
decisions are based on the responsiveness to the given therapy, risk stratification, and 
evaluation of biomarkers [8].  
Unstable angina differs from NSTEMI only in that biomarkers are not increased; 
however the treatment is the same [8].   
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ASSESSMENT   
 
Clinical judgment  
The physicians assessment remains imperative for differentiating MI from other 
potential causes of disease and should be combined with an ECG and biomarkers to 
decide whether to admit or discharge patients with suspected MI [24]. Clinical 
judgment is defined as the use of patient information (history, physical signs and 
symptoms, laboratory data, and radiologic results) combined with subjective and 
objective data (best practice or theory) that lead to a conclusion and treatment plan. 
Clinical judgment is developed through practice and analysis, leading to experience 
and knowledge. Previous studies have shown improved accuracy when adding clinical 
judgment to the ECG and biomarker findings in the assessment of patients with chest 
pain while others have reported inconclusive results regarding clinician assessment 
[25-27].  
 
Risk factors  
A common conception is that the presence of more cardiac risk factors is associated 
with a higher risk of MI. Several risk factors are associated with increased risk of 
future MI, including age, male sex, hypertension, hypercholesterolaemia, diabetes 
mellitus, smoking, family history, obesity, and physical inactivity [28]. These factors 
may increase the long-term risk of MI, but do not increase the probability of an 
ongoing MI in the ED in patients with chest pain [29-33]. 
Scoring systems 
Clinical guidelines recommend the use of a scoring system for risk stratification of 
patients with suspected MI [8] and several studies have shown increased identification 
of low-risk patients when combining a risk score with troponin measurement [29,34]. 
However, the implementation of scoring systems in clinical practice and their current 
use have been poorly investigated [26]. Some of the most common scoring systems are 
depicted in TABLE 2.  
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TABLE 2. Common scoring systems and their variables. 
Risk score Year of publication Score variables 
 
GRACE  
 
 
2003 
 
Age, Killip class, blood pressure, heart rate, creatinine 
level, the presence of cardiac arrest on admission, ECG, 
biomarkers. [35] 
 
TIMI 
  
 
2000 
 
Age, risk factors, history of coronary artery disease, 
medication, present angina ECG, biomarkers. [36] 
 
 
HEART 
 
 
2008 
 
History, ECG, age, risk factors, troponin (conventional). 
[34] 
 
 
MACS 
 
 
2014 
 
High-sensitivity cardiac troponin T, Heart-type fatty acid 
binding protein, ischaemic ECG, sweating observed, 
vomiting, systolic blood pressure <100 mm Hg, 
Worsening angina, Pain radiating to the right arm or 
shoulder. [29] 
 
Vancouver chest pain rule 
 
 
2014 
 
Age, ECG, biomarkers, prior myocardial infarction or 
nitrate use, physical examination, pain radiation. [37] 
Abbreviations: Global Registry of Acute Coronary Event (GRACE); Thrombolysis In Myocardial 
Infarction score (TIMI); History ECG Age Risk factors Troponin (HEART); Manchester Acute 
Coronary Syndromes Decision Rule (MACS). 
 
 
Non-invasive testing 
Non-invasive methods for investigating suspected NSTEMI depend on local 
resources and expertise [26]. The exercise ECG was previously the investigation 
method of choice and is still widely used in some countries. Current clinical 
guidelines do not recommend use of exercise ECG for assessment of coronary 
disease [38]. Stress echocardiography is preferred over the exercise ECG because of 
its greater diagnostic accuracy and is recommended by guidelines during admission 
or shortly after discharge [8]. Computed tomographic coronary angiography is 
indicated in patients with a clinical suspicion of coronary disease, but the clinical 
outcomes of this test have been debated [39]. In the ED at Karolinska University 
Hospital, very few or no computed tomographic coronary angiograms are performed. 
Previous studies have investigated the effectiveness of non-invasive stress testing 
compared with no testing for reducing the risk of MI and found no difference [40].  
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TROPONIN 
Historic overview 
Since the 1950s, several biomarkers have been clinically tested to diagnose  
suspected MI: aspartate transaminase, lactate dehydrogenase, myoglobin, creatine 
kinase and the CK isoenzyme MB (FIGURE 3) [41,42]. However, these biomarkers 
are not cardiac-specific; their levels increase in a variety of pathological conditions 
and can therefore not be used to distinguish between cardiac or skeletal injury [42]. 
A breakthrough in the search for a more cardiac-specific biomarker came in the 
1990s with troponin. In 1997, troponin was observed to be suitable for detection of 
myocardial damage in a clinical context, and researchers reported that it would be 
safe to discharge patients showing negative results on troponin tests [43]. 
 
 
A concern regarding missed diagnoses has accompanied the introduction of troponin 
as a clinical tool. At the turn of the millennium it was reported that even more 
specific biomarkers were needed to accurately diagnose myocardial damage and  
reduce the number of missed diagnoses [44]. In 2000, the First Global Task Force for 
MI added troponin as part of the recommended diagnostic process for suspected MI, 
supplementing ECG and physician assessment, and proposed a new definition of MI 
[45]. The definition of MI was revised a second time in 2007 [46]. In 2012, the 
definition of MI was updated for the third time in a decade and included high-
sensitivity cardiac troponin assays [3]. 
 
 
 
FIGURE 3. Timeline of the development of biomarkers for the diagnosis of MI. Abbreviations: 
Aspartate transaminase (AST); lactate dehydrogenase (LD); myoglobin (MB); creatine kinase (CK); 
CK isoenzyme MB (CK-MB); cardiac troponin (TnT); high-sensitivity cardiac troponin T (hs-cTnT). 
 
  18 
Structure 
Troponin is a protein component of the contractile apparatus of the cardiac muscle 
cell, the myocyte. The contractile unit of the cardiac muscle cell consists of myosin 
and actin, tropomyosin, and the troponin complex, as depicted in FIGURE 4. The 
troponin complex comprises three regulatory subunits: C, I and T, that control the 
interaction between actin and myosin and therefore control cardiac muscle 
contraction. Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) have unique 
isoforms in the cardiomyocyte making them suited for inclusion in immunoassays 
and diagnostic analyses [47].  
 
 
 
FIGURE 4. The troponin complex structure. Troponin I (TnI); Troponin C (TnC), Troponin T (TnT). 
Image reproduced with permission from the publisher. 
 
 
Release mechanism 
Troponin is mostly an intracellular protein. Therefore, the presence of troponin in the 
blood circulation reflects its release from cardiomyocytes. The majority of 
intracellular troponin is attached to the contractile apparatus and constitutes the 
structural pool. A minor amount of cardiac troponin, approximately 6% to 8%, is 
always detectable in the blood, and constitutes the circulating pool. This cytosolic 
pool is believed to be caused by natural turnover of cardiomyocytes and can be 
further increased by physiological conditions and physical exercise [48-50].  
 
When damage to a cardiomyocyte occurs, as in ischaemic MI, troponin is believed to 
be released from small storage areas in the cytosolic pool, followed by a slower 
release from the contractile apparatus of the cardiomyocyte as it is destroyed. This 
process results in an increased troponin concentration in the blood for days to weeks 
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[51,52]. The degree of the troponin increase and the time until its peak concentration 
is reached are dependent on the underlying cause and mechanism of the troponin 
release (FIGURE 5) [53]. The mechanism is well described during cardiomyocyte 
necrosis, but other mechanisms of troponin release that have not been completely 
clarified may be present (e.g. normal cell turnover, apoptosis, or increased cell 
membrane permeability) [53-55].  
 
 
FIGURE 5. The troponin release mechanism. Image reproduced with permission from the publisher. 
 
Recent advances in our understanding of the pathogenesis of ischaemic heart disease 
confirm that troponin turnover is increased in patients with coronary artery disease 
and heart failure [56]. These patients are believed to have a larger pool of circulating 
troponin, possibly due to coronary plaque rupture that cause microinfarctions and 
chronic troponin leakage. These patients exhibit plasma levels that correlate with the 
disease burden [57].  
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THE HIGH-SENSITIVITY CARDIAC TROPONIN T ASSAY 
The initial first-generation troponin assays, presently known as conventional assays, 
exhibited 100% sensitivity for detecting troponin in the blood 6 to 12 hours after the 
onset of chest pain. Practically, this meant that a patient required a repeated 
measurement 6 to 12 hours after the first assessment to rule out MI [46]. With 
conventional assays, the troponin concentration in healthy individuals were below 
the detection limit. Determination of the upper reference limit was problematic, 
leading to qualitative assessments and categorization of patients as troponin-positive 
(detectable) or troponin-negative (undetectable) [58]. The assays were continuously 
genetically re-engineered to reach an increased analytical sensitivity and were later 
termed sensitive assays.  
 
Further developments resulted in assays that were able to detect troponin in the blood 
with higher sensitivity and at a much earlier time point than the previous assays; 
hence they were termed high-sensitivity assays [4].  The nomenclature negative and 
positive troponin became useless because hs-cTnT was now detectable even in 
healthy individuals [59].  
 
Nomenclature 
The term “high-sensitivity” reflects the analytical characteristics of the assay. 
Several terms are present in the literature for more sensitive assays, such as “highly 
sensitive”, “high-sensitive”, “high sensitivity”, “ultrasensitive”, “novel highly 
sensitive” and “high-performance”. 
 
The 99th percentile 
An assay must meet two analytical requirements to be considered a high-sensitivity 
assay. First, the coefficient of variation must be <10% at the 99th percentile in the 
population. Second, the assay should be able to measure troponin concentrations 
below the 99th percentile and above the limit of detection for at least 50% of the 
reference population [47]. The new guidelines recommended using the 99th 
percentile of a healthy population as the cut-off for the diagnosis of MI [3]. This 
concept was introduced at a time when conventional assays detected troponin values 
in <5% of healthy individuals [45,60]. Because high-sensitivity assays are now in 
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use, more individuals without MI will be found to have normal circulating elevated 
troponin levels above the 99th percentile (approximately 9% according to a previous 
study) [59,61]. The 99th percentile is dependent upon the characteristics of the 
underlying population, and there is an ongoing debate concerning what criteria 
should be used to define a healthy population. Higher levels of troponin have been 
observed in male patients, in patients of increasing age, and patients with reduced 
kidney function as indicated by the estimated glomerular filtration rate (eGFR) [61]. 
Renal function impacts the troponin concentration, partially because of decreased 
renal clearance but mostly because of ongoing cardiac damage [62,63]. Age partially 
reflects the increased remodeling of the myocardium with subsequent cardiomyocyte 
loss. Several studies have also investigated whether sex-specific [64,65] or age-
specific cut-offs should be applied to the diagnosis of MI [61]. 
 
Characteristics 
Hs-cTnT is superior to previous generations of troponin in many ways, primarily its 
improved sensitivity and earlier detection (approximately 3 hours) of cardiomyocyte 
damage [4,66].  
 
The increased sensitivity implies that hs-cTnT detects concentrations of troponin 10 
times lower than previous assays, enabling detection of circulating normal troponin 
concentration in healthy individuals, believed to be the results of natural turnover of 
cardiomyocytes. Therefore, the troponin concentration should be quantitatively 
interpreted and has been observed to correlate well with disease severity and the 
histopathological extent of cardiac injury [67,68]. A higher hs-cTnT level at 
presentation is associated with a greater risk of MI and death [8]. With the improved 
sensitivity of these assays, it is imperative for the physician to distinguish between 
acute and chronic elevations of troponin to determine whether the patient should be 
admitted, discharged, or undergo further investigations. Causes of acute troponin 
elevation are associated with a rise and/or fall pattern of a second troponin 
measurement [3]. 
 
With respect to a low or undetectable (<5 ng/L) troponin concentration, several 
studies have investigated whether a single troponin value is enough to safely rule out 
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MI [5,6,69]. Current European guidelines recommend discharge of patients who 
present with chest pain and exhibit a hs-cTnT level of <5 ng/L if the onset of chest 
pain is persistent for >3h. If the patient has an early onset of chest pain <1 hour 
before arrival to the ED, a second measurement (delta troponin) is recommended to 
determine whether the patient should be admitted to hospital or discharged home [8]. 
The delta troponin is defined as the difference between two troponin values in the 
same patient, within a specific time interval [70]. 
 
The improved sensitivity of current troponin assays has also resulted in decreased 
specificity for the diagnosis of MI. When sensitive assays were first put into clinical 
use, an elevated troponin concentration was considered indicative of MI. Recent 
studies have shown that an elevated troponin level may be associated with multiple 
pathophysiological conditions such as heart failure, atrial fibrillation, pulmonary 
embolism, and sepsis [8]. Troponin is thus heart‐specific but not disease‐specific, and 
it provides no information about the cause or mechanism of release. The biological 
variation of hs-cTnT should also be considered when interpreting small troponin 
increases in healthy individuals [71].  
 
Prognosis 
The association between an elevated troponin level and increased long-term 
mortality in older patients and patients with cardiac disease has been shown in 
multiple studies [72,73]. A high prevalence of elevated troponin concentrations 
among seemingly healthy individuals in the general population and increased long-
term mortality has also been reported [74]. Hs-cTnT is thus currently regarded as a 
general prognostic indicator for disease and long-term mortality. How the physician 
should interpret and evaluate these elevated troponin levels on an individual-patient 
bases remains unclear. Consequently, when hs-cTnT was first implemented into 
clinical practice, clinicians were initially concerned that patients would be 
excessively admitted to hospital for observation and further investigations [70]. 
 
Resource utilization 
Serial measurements of troponin in many healthy individuals increases the length of 
stay in the ED, contributes to overcrowding, delays in testing and other 
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investigations, and lowers patient satisfaction [75,76]. Furthermore, because of the 
current uncertainty regarding how to handle elevated troponin levels, patients are 
commonly admitted to hospital, and may undergo investigations that are potentially 
harmful and unnecessary and have severe economical and health care consequences 
[40,77-80].  
 
Global use 
One existing manufacturer produces the hs-cTnT-assay. First produced in 2010, the 
Roche Elecsys 2010 system hs-cTnT has been found to be valid in terms of 
analytical sensitivity, specificity, interference, and precision [4]. This hs-cTnT assay 
has been used in clinical practice in Europe and Asia. In January 2017, it was also 
approved for use in the United States with the addition of sex-specific cut-offs. The 
sales name is Cardiac troponin T (cTnT) because the term "high-sensitivity" is 
considered to be an analytical term [81]. 
 
The use of hs-cTnT was introduced at Karolinska University Hospital on 10 
December 2010. From the start of implementation there was a calibration issue of the 
method which was detected in 2012, when batches of defective reagents were 
replaced. After the replacement, the method became even more sensitive than before; 
the Karolinska Laboratory reported that the hs-cTnT level at the 99th percentile  was 
approximately 18% higher [82,83]. 
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AIMS OF THE THESIS 
 
The overall aim of this doctoral thesis was to increase knowledge about how the 
introduction of the hs-cTnT assay in the ED has affected admissions to hospital, 
resource utilization, and patient outcomes.  
 
The specific aims were: 
 
 
Study I 
 
To determine whether a first undetectable hs-cTnT level in combination 
with a normal ECG in patients presenting with chest pain to the ED can 
safely rule out MI. 
 
Study II 
 
To determine whether patients with chest pain and an initial 
undetectable hs-cTnT level have an increased risk of revisits, 
readmissions, coronary angiography, or revascularization if they are 
admitted instead of discharged home directly from the ED. 
 
Study III 
 
To describe trends in admission rates of patients presenting with chest 
pain in the ED during the first 4 years after the introduction of the hs-
cTnT assay and investigate outcomes and effects on resource utilization 
following the ED visit. 
 
Study IV 
 
To compare survival and resource utilization between the initial 3 years 
of hs-cTnT implementation with the preceding 2 years when 
conventional troponin (cTnT) was in use. 
 
 
 
 
 
  25 
METHODS 
 
OVERVIEW 
A summary of study design and outcome for all studies are depicted in TABLE 4. 
TABLE 4. Overview of Studies I to IV. 
Study I 
Undetectable 
II 
Revisits 
III 
Trends 
IV 
Survival 
Aim To evaluate if a hs-cTnT 
level <5 ng/L and a 
normal ECG can safely 
rule out MI in the ED. 
To assess the effects of 
discharge vs. admission on 
resource utilization in patients 
with low-risk chest pain. 
To describe trends in 
admissions for chest 
pain after the 
introduction of hs-cTnT. 
To study prognosis and 
resource utilization in 
patients evaluated with hs-
cTnT compared with cTnT. 
Hypothesis Patients with chest pain, 
hs-cTnT <5 ng/L and a 
normal ECG, have a 
minimal risk of MI or 
death and can be safely 
discharged from the ED. 
Patients with chest pain, a hs-
cTnT <5 ng/L and a normal 
ECG, have an increased risk of  
revisits and resource utilization, 
if they are admitted compared 
with discharged from the ED. 
The proportion of 
patients admitted for 
chest pain has been 
reduced and mortality 
within 1 year of the ED 
visit is unaffected. 
The implementation of hs-
cTnT has improved 
survival for patients with 
chest pain in the ED. 
Resource utilization has not 
increased. 
Study design Observational cohort study 
Cohort All patients with a 
principal complaint of 
chest pain and a first hs-
cTnT level analysed in 
the ED.  
All patients with a principal 
complaint of chest pain and a first 
hs-cTnT level analysed  in the ED. 
Patients with MI within 30 days of 
the ED visit were excluded. 
All patients with a 
principal complaint of 
chest pain and a first hs-
cTnT level analysed in the 
ED. 
All patients with a 
principal complaint of 
chest pain and a first 
troponin level analysed 
in the ED. 
Study setting Karolinska University Hospital 
 Huddinge, Solna Huddinge, Solna Huddinge Huddinge, Solna 
Study period 10 Dec 2010 - 31 Dec 2012 1 Jan 2011- 20 Oct 2014 1 Jan 2009 -31 Dec 2013 
No. of patients  14,636 13,046  15,472 31,904 
Exposure hs-cTnT <5 ng/L and a 
normal ECG 
Admitted to hospital Each year (2012, 2013, 
2014) of the study period 
hs-cTnT 
Reference N/A Discharged home Year 2011  cTnT 
Outcomes 1) MI within 30 days  
2) MI within 180 or 365 
days and all-cause 
mortality within 30, 180, 
365 days 
1) revisit to the ED  
2) revisit leading to hospital 
stay, >1 revisit, coronary 
angiography or 
revascularization 
1) admission rate 
2) all-cause mortality, CV-
mortality, MI, heart failure 
or revascularization 
1) 1 year all-cause 
mortality 
2) coronary angiography 
and revascularization 
within 1 year  
Follow up 31 Dec 2012: all-cause 
mortality, MI, hospital 
stays 
 
30 June 2014: revisits. 31 Dec 
2012 : hospital stays, coronary 
angiography and 
revascularization 
30 June 2015: all-cause 
mortality. 31 Dec 2014: 
CV-mortality. 31 Dec 
2013: MI, heart failure, 
coronary angiography and 
revascularization. 
31 Dec 2014 : all-cause 
mortality.  
31 Dec 2013:  MI and 
CV-mortality. 
Statistics Survival analysis (Cox regression) 
Main findings Patients with chest pain,  
a first hs-cTnT <5 ng/L 
and a normal ECG have 
a minimal risk of MI 
and may be safely 
discharged from the ED.  
When patients with hs-cTnT < 
5 ng/L are admitted, increased 
risk of revisit to the ED, 
coronary angiography and 
revascularization was seen. 
Admissions were reduced 
by 36% during the first 4 
years of hs-cTnT use. 
Increased mortality and 
coronary angiography 
were observed.  
After the introduction of 
hs-cTnT, increased 
mortality, coronary 
angiography and 
revascularization were 
observed. 
Status Journal of American 
College of Cardiology, 
2014. 
International Journal of 
Cardiology, 2016. 
International Journal of 
Cardiology, 2017. 
Submitted. 
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Abbreviations: Myocardial infarction (MI); emergency department (ED); Not applicable (N/A); high-
sensitivity cardiac troponin T (hs-cTnT); cardiac troponin T (cTnT); cardiovascular (CV). 
 
THE DATASET 
Two separate datasets were assembled during the course of the thesis and the process 
of creating each dataset was identical. The ED at Karolinska University Hospital has a 
local administrative database containing information on the date and time of each visit, 
reason for the visit, duration of stay in the ED, and several other variables for each 
patient. Using this database, we identified all patients who presented to the ED with a 
principal complaint of chest pain. To determine which of these patients had a troponin 
level analysed at the time of the visit to the ED, we integrated archived laboratory data 
via the hospital´s Information and Technology Department. The dataset was thereafter 
sent to the National Board of Health and Welfare, where it was linked with the 
National Patient Register, the Prescribed Drug Register, and the Cause Of Death 
register, using each patient´s Swedish personal identity number [84,85]. The complete 
dataset was anonymized according to regulations and returned to the research group 
[FIGURE 6]. 
 
 
 
FIGURE 6. Dataset assembly. 
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REGISTRIES 
The National Patient Register has had nationwide coverage since 1987 and is 
maintained by the National Board of Health and Welfare. The register includes data 
from public and private health care providers regarding outpatient care, admissions and 
discharges, surgeries, and other procedures. Diagnoses, surgical procedures, and 
interventions are categorized according to the World Health Organization International 
Statistical Classification of Diseases and Related Health Problems (ICD) [86]. We 
extracted data on admissions and discharge diagnoses and interventions such as 
coronary angiography, percutaneous coronary intervention (PCI), and coronary artery 
bypass grafting (CABG). We also retrieved information on previous hospital stays for 
MI, stroke, heart failure, chronic obstructive pulmonary disease and other 
comorbidities. The register has been found to have high validity [84]. It was previously 
updated annually, but from 30 April 2015, the register has been updated monthly 
[84,87]. 
 
The Prescribed Drug Register contains data on drugs prescribed for individuals and 
dispensed prescriptions at pharmacies since 1 July 2005. The register is maintained by 
the Swedish National Board of Health and Welfare, and the number of prescriptions 
exceeds 100 million each year. The register is updated monthly [85]. 
 
Since 1961, the Cause of Death Register has been maintained by the National Board 
of Health and Welfare. The register holds data on all deceased Swedish residents, 
including age, time of death, and cause of death according to the ICD. The register is 
updated annually [88]. 
 
 
STUDY DESIGN AND POPULATION 
 
Dataset 1 was created at the start of Study I, used in Studies I and II, and includes data 
from the ED at both sites, Huddinge and Solna, of Karolinska University Hospital 
from 12 December 2010 to 31 December 2012.  
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Dataset 2, was created at the start of Study III, used in Studies III and IV, and includes 
data from the ED at both sites, Huddinge and Solna, of Karolinska University Hospital 
from 1 January 2009 to 20 October 2014. When choosing study population for Study 
III, we included only patients from the Huddinge site, from 1 January 2011 to 20 
October 2014. A description of Datasets 1 and 2 is provided in FIGURE 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY	I 
14,636 
STUDY	II 
14,636 
Age	<	25,	n=776 
Patients	with	hs-cTnT	<5	ng/L	
and	MI	within	30	days	of	the	
ED	visit,		n=41 
Patients	with	hs-cTnT	5-14	
ng/L	and	MI	within	30	days	of	
the	ED	visit,	n=	97 
Patients	with	hs-cTnT	>14	ng/L	
and	MI	within	30	days	of	the	
ED	visit,	n=	676 
Dataset	1 
14,636	patients	with	chest	pain	and	a	first	 
hs-cTnT-level	in	the	ED	at	 
Karolinska	University	Hospital	 
10	Dec	2010		–		31	Dec	2012 
 
 
 
 
13,860 
13,819 
13,722 
13,046 
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FIGURE 7. A description of Datasets 1 and 2, the study population and exclusion criteria for all studies. 
 
Study I 
From Dataset 1, we included all patients who presented to the ED with a principal 
complaint of chest pain and had a first hs-cTnT level analysed during the visit to the 
ED, (defined as the index date) from 10 December 2010 to 31 December 2012. 
Patients were categorized according to the first hs-cTnT level analysed: <5, 5-14 and 
>14 ng/L. The exposure was a hs-cTnT level of <5 ng/L and an ECG with no 
ischaemic changes.  
For patients identified with a first hs-cTnT of <5 ng/L and a diagnosis of MI within 30 
days of the visit to the ED, we retrieved the ECGs from their medical records. For each 
case we also retrieved the ECGs for two control patients, matched for age, sex and first 
hs-cTnT level. Two senior cardiologists who were blinded to the study protocol, 
assessed the ECGs. Medical records were also screened for all patients with a first hs-
cTnT level of <5 ng/L and a diagnosis of MI within 30 days, to validate the diagnosis 
of MI according to the troponin levels, and coronary angiography and/or 
echocardiography findings and to evaluate the patient´s characteristics and history. 
 
Study II 
Patients were included from the same dataset used in Study I, from 10 December 2010 
to 31 December 2012. The inclusion criteria were all patients ≥25 years, who 
presented to the ED with a principal complaint of chest pain and had a hs-cTnT level 
Dataset	2	
31,904	patients	with	chest	pain	and	a	first	
hs-cTnT	level	in	the	ED	at	
Karolinska	University	Hospital	
1	Jan	2009	—	20	Oct	2014	
	
STUDY	III	
n=	15,472	
Huddinge	only	
1	Jan	2011	–	20	Oct	2014	
STUDY	IV	
n=	31,904	
Huddinge	and	Solna	
1	Jan	2009	–	31	Dec	2013	
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analysed during the visit to the ED, (defined as the index date). The exclusion criteria 
were patients <25 years (n=776) and MI within 30 days of the visit to the ED (total, 
n=814) as depicted in FIGURE 7. Patients were categorized by their admission or 
discharge status and according to the first hs-cTnT level analysed: <5, 5-14 or >14 
ng/L. The exposure was to be admitted to hospital, while the reference was to be 
discharged home from the ED. 
 
Study III  
A second dataset was created using an identical process as for Dataset 1. From this 
dataset, we included patients aged ≥25 years who presented with chest pain to the 
Huddinge ED and who had a hs-cTnT level analysed during the visit, from 1 January 
2011 to 20 October 2014. For descriptive reasons, patients were categorized according 
to the first hs-cTnT level analysed in the ED: <5, 5-14 and >14 ng/L. The exposure 
was defined as each year (2012, 2013, and 2014) of the study period. The first year, 
2011, when the hs-cTnT method was introduced, was defined as reference.  
 
Study IV 
Study IV was based on the same dataset used in Study III. From Dataset 2, we 
included all patients aged ≥25 years who presented to the ED with a principal 
complaint of chest pain and had a hs-cTnT level analysed during the visit at both sites, 
Huddinge and Solna, from 1 January 2009 to 31 December 2013. Depending on the 
time of the ED visit, patients were analysed with either cTnT or hs-cTnT. At the 
Karolinska Laboratory, the fourth-generation troponin cTnT assay was in use from 1 
January 2009 to 9 December 2010 and this period was defined as the reference. From 
10 December 2010 to 31 December 2013, hs-cTnT was used and was defined as the 
exposure under study.  
 
BIOMARKERS 
The fifth-generation hs-cTnT assay, (Roche Diagnostics) was introduced at the 
Karolinska University Hospital Laboratory on 10 December 2010 and was used to 
analyse hs-cTnT in Studies I to IV.  The method has a limit of detection of 5 ng/L and 
a limit of blank of 3 ng/L. The 99th percentile cut-off is 14 ng/L, and the assay has a 
coefficient of variation of <10% at 13 ng/L [4]. 
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The fourth-generation cardiac troponin cTnT assay was in use at the Karolinska 
University Hospital Laboratory until 9 December 2010. The method has a limit of 
detection of 0.01 mikrog/L, a 99th percentile cut-off at <0.01 and a coefficient of 
variation of 10% at 0.03 mikrog/L [89]. 
 
 
OUTCOME AND FOLLOW UP 
 
Study I 
The primary outcome was fatal or non-fatal type 1 MI within 30 days of the ED visit. 
The secondary outcomes were MI within 180 and 365 days and all-cause mortality 
within 30, 180 and 365 days after the ED visit. The patients first hs-cTnT level on the 
index date initiated the follow up period, which ended on 31 December 2012 for 
hospital stays, MI, and all-cause mortality. 
 
Study II 
The primary outcome was a revisit to the ED, regardless of cause. The secondary 
outcomes were a revisit to the ED within 30, 90, 180, and 365 days; a revisit to the ED 
leading to a hospital stay, >1 revisit to the ED, and coronary angiography or 
revascularization (defined as PCI or CABG). The patients first hs-cTnT level on the 
index date initiated the follow up period, which ended 30 June 2014 for revisits and 31 
December 2012 for hospital stays, coronary angiography, and revascularization. 
 
Study III 
The primary outcome was the admission rate since the introduction of hs-cTnT. The 
secondary outcomes were all-cause mortality, cardiovascular and non-cardiovascular 
mortality, and major adverse cardiac events (MI, heart failure, or revascularization) 
within 1 year of the visit to the ED.  
The proportions of admitted patients with chest pain were calculated each year during 
the study period (2011, 2012, 2013, and 2014). The proportions of patients admitted 
for abdominal pain and dyspnoea were also calculated for comparison. Moreover, 
proportions of patients with chest pain who underwent coronary angiography and 
revascularization within 1 year of the visit to the ED were also calculated. 
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Patients were included on their first visit to the ED with a principal complaint of chest 
pain and followed up until (a) the outcome under study occurred (MI, heart failure, or 
revascularization), (b) the patient died, (c) a new visit to the ED with a principal 
complaint of chest pain occurred or (d) 1 year had passed since the first visit to the ED 
(index visit). If the patient presented to the ED with chest pain within 1 year or any 
outcome had occurred, a new follow-up period was initiated. Patients were followed 
until 30 June 2015 for all-cause mortality, 31 December 2014 for cause-specific 
mortality and 31 December 2013 for the outcome MI, heart failure, coronary 
angiography and revascularization. 
 
Study IV 
The primary outcome was 1-year (a) all-cause mortality, (b) coronary angiography, 
and (c) revascularization defined as PCI or CABG. Follow-up started at the index visit 
and ended 1 year after the ED visit, at the time of death or at the end of the study. The 
end of the study was 31 December 2014 for all-cause mortality and 31 December 2013 
for MI and cause-specific death. If a patient revisited the ED because of chest pain and 
had a concurrent troponin measurement, a new follow-up period started. It was 
therefore possible for the same patient to first be exposed to the cTnT method and later 
to the hs-cTnT method. 
 
 
STATISTICAL ANALYSIS 
Data management and statistical analyses were conducted using the World 
Programming System, version 3.0 (World Programming Ltd., Hampshire, UK). A Cox 
proportional hazards model was performed using R version 3.0.2 (R Foundation for 
Statistical Computing, Vienna, Austria). 
 
Study I   
We stratified patients into categories according to their first hs-cTnT-level: <5, 5 to 14, 
and >14 ng/L and calculated the absolute risk, negative predictive value (NPV) and 
incidence of MI and death with a follow-up of 30, 180 and 365 days. In addition, Cox 
proportional hazards model was used to calculate hazard ratios (HRs) with 95% 
confidence intervals (CI) for the potential association between the exposure (not 
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admitted with the reference admitted) and the outcome (time to death). In the Cox 
model, we adjusted for age, sex, diabetes, prior MI, and eGFR.  
 
Study II  
Patients were stratified by their first hs-cTnT-level: <5, 5–14, and >14 ng/L and by 
their admission or discharge status. Within each of the six strata, the absolute risk and 
incidence per 1000 person-years with 95% CI were calculated for the primary and 
secondary outcomes. Also, Cox proportional hazard models were used to calculate the 
HRs with 95% CI for the possible association between admitted versus discharged 
patients and the primary and secondary outcomes stratified by the three hs-cTnT 
categories (<5, 5–14, and >14 ng/L). This estimation was conducted for three models: 
1) crude; 2) adjusted for age and sex; and 3) adjusted for age, sex, eGFR, diabetes, 
prior MI, prior stroke, chronic obstructive pulmonary disease, and heart failure. Age 
and eGFR were defined as continuous variables. A total of 122 patients had missing 
eGFR and were excluded from the Cox proportional regression models. We calculated 
cumulative survival and constructed a survival curve using the Kaplan-Meier method. 
 
Study III  
HRs with 95% CIs for the outcomes all-cause mortality, cardiovascular or non-
cardiovascular mortality, and major adverse cardiac events (MI, revascularization, or 
heart failure) within 1 year of the ED visit for chest pain were estimated using Cox 
proportional hazard models. HRs were adjusted for age, sex, eGFR, prior stroke, prior 
MI, chronic obstructive pulmonary disease, or heart failure (defined as primary 
discharge diagnosis from hospital stay before study onset), and diabetes (defined as 
ongoing medication with any hypoglycaemic agent).  
 
Study IV 
Cox regression models were used to calculate HRs with 95% CIs for all-cause 
mortality, cardiovascular mortality, coronary angiography and revascularization during 
1 year of follow-up after the visit to the ED. In addition, HRs with 95% CIs were 
calculated in the following subgroups: 1) patients who were discharged directly from 
the ED 2) patients who were admitted, but did not have MI, and 3) patients who were 
admitted and diagnosed with MI. The estimation was made for three models: 1) crude 
2) adjusted for age and sex, and 3) adjusted for age, sex, eGFR, prior MI, prior stroke, 
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heart failure, chronic obstructive pulmonary disease, diabetes, prior revascularization, 
and ongoing medication with aspirin, statins, beta-blockers, or angiotensin-converting 
enzyme inhibitors/angiotensin receptor blockers.   
 
 
ETHICAL CONSIDERATIONS  
 
Studies I to IV 
All studies adhered to the guidelines of the Declaration of Helsinki. Approval of the 
study protocols was granted by The Regional Ethical Review Board in Stockholm.  
Personal information was handled according to regulations in the Personal Data 
Protection Act [90]. All data were analysed and saved in anonymized form according 
to regulations that protected the integrity of the patients. Personal identification 
numbers were replaced by consecutive numbers to prevent identification of single 
individuals in the dataset. In general, large register-based studies containing 
anonymized information, have a minimal risk of single individuals being exposed to a 
violation of personal integrity. 
 
Study I 
In the first study (DNR 2013/843-31/3 and 2013/1512-32), medical records were 
screened to validate the diagnosis of MI and evaluate the medical history and risk 
factors. During the review, only relevant non-personal information was recorded.  
However, there may have been a potential ethical issue concerning creation of the 
overview, which described each of the patient´s signs and symptoms during the 
episode, because very few patients presented with a first hs-cTnT level of <5 ng/L and 
MI within 30 days.  
The patient records were screened on computers located at Karolinska University 
Hospital. No records were saved or printed outside the hospitals computer system. 
During interpretation of ECGs, all records were anonymized and personal 
identification numbers were replaced with consecutive numbers. The process took 
place in a locked room at Karolinska University Hospital in Huddinge and no records 
left this room. Therefore, confidentiality and anonymity were ensured during the data 
processing.  
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Study III 
In the third study (DNR 2015/1903-32), we reviewed the medical records of 100 
randomly chosen patients from 2013 to 2014 for information on risk assessment and 
the use of any scoring system. Again, the screening process was performed on 
computers located in a locked room at Karolinska University Hospital in Huddinge. 
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RESULTS AND METHODOLOGICAL DISCUSSIONS 
 
STUDY I  
 
Results 
Patient characteristics  
In total, 14,636 patients with chest pain were included and 61% (n = 8,907) of these 
presented with a first hs-cTnT level of <5 ng/L (FIGURE 8). Patients with undetectable 
hs-cTnT were younger and less likely to have diabetes or chronic cardiovascular 
disease. With increasing levels of hs-cTnT, patients were older, more often men, and 
had more comorbidities (TABLE 6). 
 
Primary outcome measure 
Of the 8,907 patients with a first hs-cTnT level of <5 ng/L, only 44 patients were 
diagnosed with MI within 30 days. Some patients were excluded from further analysis; 
2 had periprocedural MI, 3 did not meet the current criteria for MI [3], and 24 had 
initial ECG changes. The remaining 15 patients were older and more often men with 
cardiovascular disease (FIGURE 9). A first hs-cTnT level of <5 ng/L in combination 
with a normal ECG showed a 99.8% NPV for MI within 30 days (CI 99.7-99.9) and a 
0.17% absolute risk for MI (CI 0.09-0.27) (TABLE 7). 
 
Secondary outcome measures 
 
A total of 39 patients with hs-cTnT <5 ng/L developed MI 30 to 365 days after 
discharge from the ED, resulting in an incidence rate of 7.36 (CI 5.55-9.58) per 1,000 
person-years. 
The NPV for death within 30 days for patients with a first hs-cTnT level of <5 ng/L 
was 100% (CI 99.9-100.0). During the first 365 days after discharge from the ED, 38 
deaths ocurred; only 2 deaths had cardiovascular causes (TABLE 7). Among patients 
with a first hs-cTnT <5 ng/L, there was no difference in the risk of death within 365 
days between those who were admitted to hospital or those who were discharged home 
(HR 0.73, 95% CI 0.48-1.12). 
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TABLE 7. Absolute risk of MI or death in association with hs-cTnT levels. 
 hs-cTnT (ng/L) 
 <5 5-14 >14 
Myocardial infarction     
30 days                                                            
Number of events  15 97 676 
Absolute risk  0,17 (0,09-0,27) 3,08 (2,48-3,68) 26,2 (24,5-27,9) 
NPV  99,8 (99,7-99,9) 96,9 (96,3-97,5) 73,8 (72,1-75,5) 
Death    
30 days 
Number of events  2 13 66 
Absolute risk 0,023 (-0,0087-0,054) 0,41 (0,19-0,64)  2,56 (1,95-3,17) 
NPV 100 (99,9-100) 99,6 (99,4-99,8) 97,4 (96,8-98,1) 
365 days  
Number of events 
 
38 
 
108 
 
342 
Absolute risk 0,43 (0,29-0,56) 3,43 (2,79-4,06) 13,3 (12,0-14,6) 
NPV 99,6 (99,4-99,7) 96,6 (95,9-97,2) 86,7 (85,4-88,0) 
 
Absolute risks and negative predictive values are given as percentages with 95% confidence 
intervals in brackets. Abbreviations: negative predictive value (NPV); high-sensitivity cardiac 
troponin T (hs-cTnT). 
 
TABLE 6. Characteristics of patients in the study population of Study I. 
  hs-cTnT  (ng/L) 
 All patients <5  5-14 >14 
Number of patients, (%) 14,636 8,907 (61) 3,150 (22)          2,579 (18) 
Age, years 55 (19) 47 (15) 63 (16) 71 (15) 
Female sex, (%) 48 53 41 37 
eGFR 15–30 mL/min/1.73 m2 , (%) 2,1 0,03 0,74 11 
Diabetes mellitus, (%) 9,5 4,7 14 21 
Prior MI, (%)  8,5 4 14 39 
Prior hospitalization for CHF, (%) 5,7 1,4 8,2 22 
 
Age and GFR are given as means with standard deviations. Abbreviations: high-sensitivity cardiac 
troponin T (Hs-cTnT); estimated glomerular filtration rate (eGFR); myocardial infarction (MI); 
congestive heart failure (CHF).  
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FIGURE 8. The study population of Study I. Abbreviations: emergency department (ED), high-
sensitivity cardiac troponin T (hs-cTnT). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 9. Patients with a first undetectable hs-cTnT and MI within 30 days. Abbreviations: high-
sensitivity cardiac troponin T (hs-cTnT); myocardial infarction (MI). 
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Discussion 
This study showed that a first single undetectable hs-cTnT level in combination with a 
non-ischaemic ECG can be used to safely rule out MI in the ED. 
 
The major strength of the study was the large unselected study population comprising 
patients with chest pain which is representative of many EDs globally in similar health 
care settings. 
A main limitation of the study is that we had no clinical information on signs and 
symptoms upon arrival to the ED. Additionally, we had no information on whether any 
risk scoring system had been used during the evaluation of the patient. Another 
limitation is that we were unable to perform a sex- or age-stratified analysis because of 
the small number of patients (n = 15) with MI and no ECG-changes. These patients´ 
ages ranged from 39 to 72 years and only 4 of the 15 patients were women.  
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STUDY II 
 
Results 
Patient characteristics 
Among 13,046 included patients, 34% were admitted to hospital. In total, 22% (n = 
1,825) of all patients with a first hs-cTnT level of <5 ng/L were admitted. Among 
patients with undetectable hs-cTnT levels, those who were admitted were older, 
predominantly men, and more likely to have diabetes, MI or prior revascularisation 
compared with those who were discharged (TABLE 8). 
 
Primary outcome measure 
A total of 59% of all patients revisited the ED at least once during a mean follow-up of 
516 days. The likelihood of a revisit in patients with a hs-cTnT level of <5 ng/L 
increased by 12% during follow-up (adjusted HR 1.12, 95% CI 1.04–1.20) for those 
who were admitted to the hospital compared with those who were discharged from the 
ED. Patients with hs-cTnT levels of >14 ng/L showed a trend toward fewer revisits by 
11% if admitted (adjusted HR 0.89, 95% CI 0.79–1.00), as shown in TABLE 9. The 
unadjusted risk of revisits was increased in patients with a hs-cTnT level of ≤14 ng/L 
and decreased in those with a hs-cTnT level of >14 ng/L throughout the follow-up 
period (FIGURE 10).  
 
Secondary outcome measures 
A total of 13% of patients revisited the ED within 30 days. Patients with a hs-cTnT 
level of <5 ng/L who were admitted had a 24% higher risk of revisits (adjusted HR 
1.24, 95% CI 1.05–1.46) compared with patients who were discharged at the first ED 
visit (TABLE 10). The likelihood of a revisit leading to a hospital stay was almost 
doubled (HR 1.84, 95% CI 1.59–2.12) in patients with a hs-cTnT level of <5 ng/L who 
were admitted versus discharged at the first visit (TABLE 11). The likelihood of 
undergoing coronary angiography or revascularization was more than three-fold higher 
in patients with a hs-cTnT level of <5 ng/L who were admitted to hospital than 
discharged from the ED (HR 3.39, 95% CI 2.52–4.56 and HR 3.34, 95% CI 2.11-5.29 
respectively) (TABLE 12).  
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TABLE 8. Characteristics of patients in the study population of Study II.  
 hs-cTnT (ng/L) 
        < 5  5-14  > 14  
        
Discharged Admitted Discharged Admitted Discharged Admitted 
Number of patients 6,360 1,825 1,691 1,288 467 1,415 
Age (SD), years  47 (14) 56 (13) 62 (16) 68 (13) 73 (15) 73 (15) 
Female sex, n (%) 54 51 42 41 43 40 
Diabetes mellitus (%) 4,0 8,3 12 16 20 24 
Prior MI (%)  2,4 9,0 9.0 17 19 23 
Prior 
revascularisation 
2,8 10 10 19 21 19 
 
Abbreviations: high-sensitivity cardiac troponin T (hs-cTnT); standard deviation (SD); 
myocardial infarction (MI). 
 
 
TABLE 9. Revisits to the ED associated with admission to hospital compared with discharge home and 
hs-cTnT level.	
hs-cTnT (ng/L) 
	 < 5	 5-14	 >14	
	 Discharged	 Admitted	 Discharged	 Admitted	 Discharged	 Admitted	
Revisit to the ED	 	 	 	 	 	 	
No cases/no patients	 3,259/6,360	 1,089/1,825	 984/1,691	 848/1,288	 386/467	 1,128/1,415	
HR, adjusted  
*full model	 Referent	 1.12  (1.04–1.20) Referent	 1.09  (0.99–1.20)	 Referent	 0.89  (0.79–1.00)	
 
Abbreviations: hazard ratio (HR); number (No); high-sensitivity cardiac troponin T (hs-cTnT). 
*Multivariable adjustment in the full model was made for age, sex, diabetes, chronic obstructive 
pulmonary disease, prior myocardial infarction, heart failure, or stroke, and estimated glomerular filtration 
rate.  
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FIGURE 10. Survival free of revisit to the emergency department in patients who were admitted to 
hospital or discharged home at the index visit, stratified for the first hs-cTnT level analysed. 
Abbreviations: high-sensitivity cardiac troponin T (hs-cTnT). 
 
 
 
 
 
 
TABLE 10. Revisit to the ED associated with admission compared with discharge home in relation to hs-cTnT 
level. 
  hs-cTnT (ng/L)  
 < 5 5–14  >14  
 Discharged Admitted Discharged Admitted Discharged Admitted 
30 days       
Revisits (%) 566 (8.9%) 221 (12%) 211 (12%) 198 (15%) 122 (26%)  313 (22%) 
HR, 95% CI Referent 1.24 (1.05-1.46) Referent 1.21 (1.00-1.48) Referent 0.86 (0.70-1.06) 
 
Abbreviations: high-sensitivity cardiac troponin T (hs-cTnT); hazard ratio (HR); confidence interval (CI).  Hazard 
ratios were adjusted for age, sex, diabetes, chronic obstructive pulmonary disease, prior myocardial infarction, 
revascularisation, heart failure, or stroke, and estimated glomerular filtration rate.  
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TABLE 11. Revisit to the ED leading to admission, and >1 revisit to the ED associated with admission to hospital 
compared with discharge home in relation to hs-cTnT level. 
  hs-cTnT (ng/L)  
     < 5  5-14 >14  
 Discharged Admitted Discharged Admitted Discharged Admitted 
Revisit to the ED leading to admission     
No cases/no patients 500/6,306 327/1,802 289/1,680 394/1,277 177/463 643/1,396 
HR, adjusted *full model Referent 1.84 (1.59-2.12) Referent 1.54 (1.32-1.79) Referent 1.12 (0.94-1.32) 
       
More than 1 revisit to the ED     
No cases/no patients     1,876/6,306 723/1,802 653/1,680 587/1,277 308/463 859/1,396 
HR, adjusted *full 
model  
Referent 1.22 (1.12–1.33) Referent 1.09 (0.97–1.22) Referent 0.88 (0.78–1.00) 
 
Abbreviations: high-sensitivity cardiac troponin T (hs-cTnT); number (No); emergency department (ED); hazard ratio 
(HR); confidence interval (CI); *Multivariable adjustment in the full model was made for age, sex, diabetes, chronic 
obstructive pulmonary disease, prior myocardial infarction, revascularisation, heart failure, or stroke, and estimated 
glomerular filtration rate. Absolute risks, hazard ratios and incidence rates are given with 95% confidence intervals in 
brackets. 
 
 
 
TABLE 12. Likelihood of undergoing coronary angiography or revascularization if admitted to hospital compared with 
discharged home in relation to hs-cTnT level. 	 	 hs-cTnT (ng/L)	 	
 <5 5–14 >14 
 Discharged Admitted Discharged Admitted Discharged Admitted 
 
Coronary angiography 
 
      
No cases/no patients  85/6,306 98/1,802 70/1,680 90/1,277 33/463 106/1,396 
HR, adjusted *full model  Referent 3.39 (2.52–4.56) Referent 1.41 (1.03–1.94) Referent 1.04 (0.70–1.54) 
       
Revascularization 
 
      
No cases/no patients 34/6,306 42/1,802 35/1,680 50/1,277 20/463 56/1,396 
HR, adjusted *full model  Referent 3.34 (2.11-5.29) Referent 1.54 (1.00–2.38) Referent 0.90 (0.54–1.50) 
 
Abbreviations: high-sensitivity cardiac troponin T (hs-cTnT); number (No); hazard ratio (HR); confidence interval (CI); *Multivariable 
adjustment in the full model was made for age, sex, diabetes, chronic obstructive pulmonary disease, prior myocardial infarction, heart 
failure, or stroke, and estimated glomerular filtration rate. Hazard	ratios	are	given	with	95%	confidence	intervals	in	brackets 
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Discussion 
Patients with low-risk chest pain, who were admitted to the hospital instead of 
discharged home, revisited the ED more often than if they were discharged. They also 
underwent coronary angiography and revascularization to a greater extent than did 
discharged patients. 
 
After being discharged directly from the ED, patients may have visited other hospitals 
in the Stockholm area or elsewhere in the country. However, this information was not 
known to us and was the main limitation of the study. Another limitation was the lack 
of information on the patients´medical history, lifestyle factors, and clinical signs 
suggestive of MI (e.g., diaphoresis, vomiting, or radiating chest pain), which possibly 
influenced the likelihood of admission to the hospital. Even so, it seems less likely that 
the clinical presentation at the first visit influenced their likelihood of a revisit to the 
ED after discharge. It is thus unlikely that this lack of information would have 
confounded the results. Unknown residual confounding that we could not adjust for 
might have been present. However, we do not believe that these potential unknown 
comorbidities led to an increased likelihood of clinical investigations. Additionally, we 
had no information on whether non-invasive tests such as exercise ECG or stress 
echocardiography was performed before coronary angiography and whether it may 
have influenced the increased likelihood of invasive testing. Finally, the study lacked 
information on the patient´s coronary angiography and revascularization findings,  
which may have contributed to a more complete understanding of the study results. 
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STUDY III 
 
Results 
 
Patient characteristics  
The clinical characteristics of the study population were stable over time, but the 
proportion of patients with a hs-cTnT level of <5 ng/L changed significantly from 62% 
in 2011 to 42% in 2014 (TABLE 13).  
 
Primary outcome measure  
A relative 36% decrease in admissions for chest pain was observed during the first 4 
years of using the hs-cTnT assay (FIGURE 11). The total hospital admission rate, 
irrespective of complaint, was stable, and admissions for abdominal pain and 
dyspnoea, remained virtually unchanged (FIGURE 11). The largest relative increase in 
discharges was found in patients with a hs-cTnT level of >14 ng/L, (15% to 32%) 
(FIGURE 12).  
 
Secondary outcome measures 
Within 1 year of the ED visit, the absolute risk of death increased from 2.8% to 3.9%. 
The risk of all-cause mortality significantly increased, from 26% (adjusted HR 1.26, 
95% CI 1.00-1.58) to 51% (adjusted HR 1.51, 95% CI 1.18-1.92) but for non-
cardiovascular deaths only, the risk increased from 34% (adjusted HR 1.34, 95% CI 
1.00-1.80) to 85% (adjusted HR 1.85, 95% CI 1.34-2.55) (TABLE 14). There was a 
significant 6.8% to 9.6% increase in coronary angiography performed within 1 year of 
the visit for chest pain (TABLE 15), and this was most prominent in patients with a hs-
cTnT level of 5-14 ng/L (8.2% to 11%) and >14 ng/L (15% to 20%). In patients with 
undetectable hs-cTnT levels, the number of coronary angiographies decreased from 
4.2% to 2.8%. Parallel to this finding was a slight overall increase in revascularizations 
(4.6% to 5.2%), which was most prominent in patients with a hs-cTnT level of 5-14 
ng/L (TABLE 15).   
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TABLE 13. Characteristics of patients in the study population of Study III. 
  2011 
 
2012 
 
2013 
 
2014‡ 
 
Number of patients  
 
4,120 
 
4,199 
 
3,937 
 
3,216 
Number of visits  4,921 4986 4,623 3,707 
Age, years, mean (SD) 59 (17) 58 (17) 58 (17) 58 (17) 
Men, % 2,597 (53) 2,581 (52) 2,496 (54) 1,962 (53) 
eGFR <60 ml/min</1.73 m2, % 4,240 (86) 4,254 (85) 3,985 (86) 3,196 (86) 
*Prior MI, % 762 (16) 731 (15) 731 (16) 548 (15) 
*Prior heart failure, % 471 (10) 481 (10) 443 (10) 310 (8) 
*Diabetes, % 637 (9) 617 (12) 593 (13) 519 (14) 
Hs-cTnT < 5 ng/l, % 3,069 (62) 2,295 (46) 1,761 (38) 1,571 (42) 
Hs-cTnT 5–14 ng/l, % 913 (19) 1,635 (33) 1,760 (38) 1,277 (34) 
Hs-cTnT > 14 ng/l, % 939 (19) 1,056 (21) 1,102 (24) 859 (23) 
†MI during hospital stay, % 281 (6) 235 (5) 244 (5) - 
 
Abbreviations: standard deviation (SD); estimated glomerular filtration rate (eGFR); high-sensitivity  
cardiac troponin T (hs-cTnT); myocardial infarction (MI). *Data available until 2013, †Data not  
available for 2014. ‡Data available until 20 October 2014. 
 
 
 
 
 
FIGURE 11. Admission rates for abdominal pain, chest pain, and dyspnoea from 2011 to 2014. 
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 FIGURE 12. Proportion of discharged patients with chest pain from 2011 to 2014 in association with 
 high-sensitivity cardiac troponin T- levels. 
 
 
 
TABLE 14. HRs for mortality within 1 year of the visit to the ED for all patients with chest pain. 
 2011 2012 2013 2014* 
All patients 4921 4986 4623 3707 
All-cause mortality   
Deaths, n (%) 140 (2.8) 165 (3.3) 138 (3.0) 143 (3.9) 
HR, 95% CI, crude Referent 1.14 (0.91-1.44) 1.00 (0.79-1.27) 1.29 (1.01-1.64) 
HR, 95% CI, adjusted Referent 1.26 (1.00-1.58) 1.17 (0.92-1.49) 1.51 (1.18-1.92) 
Cardiovascular mortality    
Deaths, n (%) 57 (1.2) 64 (1.3) 62 (1.3) 34 (0.92) 
HR, 95% CI, crude Referent 1.01 (0.78-1.60) 0.99 (0.68-1.14) 0.94 (0.61-1.45) 
HR, 95% CI, adjusted Referent 1.12 (0.78-1.60) 1.15 (0.80-1.68) 1.09 (0.70.1.69) 
Non-cardiovascular mortality    
Deaths, n (%) 83 (1.7) 101 (2.0) 76 (1.6) 73 (2.0) 
HR, 95% CI, crude Referent 1.23 (0.99-1.63) 0.99 (0.72-1.36) 1.63 (1.18-2.25) 
HR, 95% CI, adjusted Referent 1.34 (1.00-1.80) 1.13 (0.83-1.55) 1.85 (1.34-2.55) 
 
Abbreviations: hazard ratio (HR); confidence interval (CI); myocardial infarction (MI). Hazard ratios were 
adjusted for age, sex, eGFR, prior stroke, MI, COPD, heart failure and diabetes. *Last patient was included 
October 20, 2014, and information for MI, heart failure, and revascularization was not available for 2014. 
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TABLE 15. Trends for coronary angiography and revascularization within 1 year of the ED visit. 
 2011 2012 2013 
 
Coronary angiography  
   
All patients, %  6.8% 9.0% 9.6%  
<5 ng/L 4.2% 3.8% 2.8% 
5-14 ng/L 8.2% 12% 11% 
>14 ng/L 15% 17% 20% 
 
PCI or CABG 
   
All patients, % 4.6% 5.5% 5.2% 
<5 ng/L 2.1% 2.2% 1.4% 
5-14 ng/L 5.6% 7.0% 6.7% 
>14 ng/L 13% 11% 9.2% 
 
Abbreviations: coronary artery bypass grafting (CABG); emergency department (ED); percutaneous 
coronary intervention (PCI).  
 
 
 
Discussion 
The results of this study showed a 36% relative decrease in admission rates during the 
first 4 years of hs-cTnT use in clinical practice in the ED. The greatest decrease in 
admissions was found in patients with a hs-cTnT level of >14 ng/L, who are often 
older and have more comorbidities than patients with lower hs-cTnT levels. The 
increased mortality in parallel with the reduced admission rate for patients with a hs-
cTnT level of >14 ng/L is of great concern and needs more attention. The aim of the 
study was to evaluate trends in admissions and not to report prognosis, hence mortality 
rates must be interpreted with caution. HRs varied during the study period and 
sometimes independently of the decreasing number of admissions. 
 
The proportion of patients with a hs-cTnT level of <5 ng/L was 62% in 2011 and 
decreased to 42% in 2014. This is explained by the increased sensitivity of the hs-
cTnT assay after the change of faulty batches of reagents, which were replaced in 
April 2012 [82,83]. Another limitation of the study is that other unknown external 
factors may have influenced the decreased admission rate of patients with chest pain. 
Equally, we had no information from other hospitals that may have allowed for 
comparison with our results. 
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STUDY IV 
Results 
 
Patient characteristics  
During the 5-year study period, 31,904 patients with chest pain visited the ED. Their 
clinical characteristics were nearly unchanged, as shown in TABLE 16. The proportion 
of patients with a troponin level above the 99th percentile was 6,8% in 2009 and 6,5%  
in 2010 and increased after the introduction of the hs-cTnT assay to 20%, 21%, and 
23% in 2011, 2012, and 2013 respectively. The incidence of MI decreased slightly 
despite the increased sensitivity of the troponin assay (TABLE 16). 
 
Primary outcome measure 
The risk of all-cause mortality increased by 15% in patients analysed with hs-cTnT 
(adjusted HR 1.15, 95% CI 1.02–1.29) compared with those who underwent testing 
with cTnT (TABLE 17); however cardiovascular mortality was stable (HR 1.13, 95% CI 
0.93–1.39). The likelihood of undergoing coronary angiography and revascularization 
during the hs-cTnT testing period was increased by 13% (adjusted HR 1.13, 95% CI 
1.00–1.28) and 18% (adjusted HR 1.18, 95% CI 1.01-1.37), respectively (TABLE 17).  
 
The reasons for undergoing revascularization during the two time periods changed as 
shown in TABLE 18. Initially, 31% of patients underwent revascularization for MI and 
32% for unstable angina. During the later period, when hs-cTnT was in use, 49% of 
patients underwent revascularization for MI and 17% for unstable angina (TABLE 18). 
Among patients with chest pain who were admitted to the hospital, but were not 
diagnosed with MI, the all-cause mortality rate was increased by 22% (adjusted HR 
1.22, 95% CI 1.05–1.42) (TABLE 19).  
 
When analyses were restricted to patients tested with batches of reagents that were not 
affected by the calibration issue from 25 April 2012 to 31 December 2013, the results 
showed that these patients had a 22% increased risk of all-cause mortality (adjusted 
HR 1.22, 95% CI 1.06-1.39) and a 31% increased risk of cardiovascular mortality 
(adjusted HR 1.31, 95% CI 1.04-1.66). The associations between being tested with hs-
cTnT from 8 December 2010 to 24 April 2012 and the risks of all-cause and 
cardiovascular mortality were not statistically significant (TABLE 20). 
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TABLE 16.  Characteristics of patients in the study population of Study IV. 
 
Year 
 
2009 
 
2010 
 
2011            
 
2012 
 
2013 
 
Number of patients  
 
5029 
 
6159 
 
6963 
 
6929 
 
6824 
Number of visits  5765 7149 8202 8131 7967 
Admitted, n (%) 
Age (years) 
3379 (59) 
58.7 (17) 
4287 (60) 
59.0 (17) 
5259 (64) 
58.1 (17) 
4811 (59) 
57.4 (17) 
4222 (53) 
57.3 (17) 
Men (%) 3024 (52) 3815 (53) 4411 (54) 4253 (52) 4267 (54) 
eGFR >60 ml/min/1.73 m2, % 4714 (82) 6007 (85) 6961 (85) 6852 (85) 6785 (86) 
Prior MI*, % 773  (13) 1063 (15) 1160 (14) 1102 (14) 1147 (14) 
Prior heart failure, % 572 (9.9) 675 (9.4) 773 (9.4) 714 (8.8) 707 (8.9) 
cTnT > 0.03 µg/L, % 393 (6.8) 463 (6.5) N/A N/A N/A 
Hs-cTnT > 14 ng/L, % N/A N/A 1676 (20) 1712 (21) 1808 (23) 
Prior revascularization, % 774 (13) 1067 (15) 1138 (14) 1141 (14) 1124 (14) 
MI during hospital stay** 302 (5.2) 364 (5.1) 424 (5.2) 362 (4.4) 372 (4.7) 
Abbreviations: estimated glomerular filtration rate (eGFR); myocardial infarction (MI); cardiac troponin 
T (cTnT); high-sensitivity cardiac troponin T (hs-cTnT). *Includes only MI as a primary diagnosis.   
** Includes MI as discharge diagnoses in any position (primary, secondary etc).	 
 
 
 
TABLE 17. HRs for all-cause mortality, cardiovascular mortality, coronary angiography and 
revascularization during 1 year after the visit to the ED for all patients with chest pain from 2009 to 
2013.   
 Biomarker assay 
 cTnT hs-cTnT 
 
Total, n  
 
12,485 
 
24,729 
All-cause mortality*   
No. of events 457 828 
HR (adjusted full model) Referent 1.15 (1.02-1.29) 
CV mortality**   
No. of events 164 270 
HR (adjusted full model) Referent 1.13 (0.93-1.39) 
Coronary angiography    
No. of events 412 731 
HR (adjusted full model) Referent 1.13 (1.00-1.28) 
Revascularization   
No. of events 269 484 
HR (adjusted full model) Referent 1.18 (1.01-1.37) 
Adjusted full model: age, sex, comorbidities (defined as prior MI, stroke, heart failure, 
chronic obstructive pulmonary disease, estimated glomerular filtration rate (eGFR) , diabetes, 
prior revascularization, and ongoing medication with aspirin, statins, betablockers, or 
angiotensin converting enzyme inhibitor/angiotensin receptor (ACE/ARB).  
Abbreviations: myocardial infarction (MI); cardiac troponin T (cTnT); high-sensitivity  
cardiac troponin T (hs-cTnT); hazard ratio (HR). 
* Follow-up for all-cause mortality ends 14-12-31.  
**Follow-up for cardiovascular mortality ends December 31, 2013.  
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TABLE 18. Discharge diagnoses for patients undergoing revascularization within 1 year after the visit to 
the ED because of chest pain from 2009 to 2013. 
 
 
Biomarker assay 
 
 
Diagnoses 
 
cTnT 
 
hs-cTnT 
   
Total, n 269 484 
MI, n (%)  83 (31) 239 (49) 
Unstable angina, n (%)  85 (32) 83 (17) 
Angina, n (%)  81 (30) 111 (23) 
Other, n (%) 20 (7) 51 (11) 
 
Abbreviations: myocardial infarction (MI); cardiac troponin T (cTnT); high-sensitivity cardiac troponin 
T (hs-cTnT). 
 
 
 
 
TABLE 19. HRs for all-cause mortality for patients with chest pain from 2009 to 2013.   
 Biomarker assay 
 cTnT hs-cTnT 
 
Total, n 
 
12,367 
 
24,568 
 
Discharged 
  
No. of visits, N 7,152  15,469 
Proportion discharged, N/n (%) 
No. of events (%) 
58 
121 (1.69) 
63 
217 (1.40) 
HR (adjusted full model) Referent 1.03 (0.83-1.30) 
 
Admitted, non-MI 
  
No. of visits 4,573 7,947 
No. of events (%) 261 (5.71) 513 (6.46) 
HR (adjusted full model) Referent 1.22 (1.05-1.42) 
 
Admitted, MI 
  
No. visits 642 1,152 
No. of events (%) 75 (11.7) 98 (8.51) 
HR (adjusted full model) Referent 0.96 (0.71-1.31) 
Adjusted full model: age, sex, comorbidities defined as prior MI, stroke, heart failure, COPD, eGFR, 
diabetes, prior revascularization, and ongoing medication with aspirin, statins, betablockers, or 
ACE/ARB. 
Abbreviations: myocardial infarction (MI); chronic obstructive pulmonary disease (COPD); estimated 
glomerular filtration rate (eGFR); cardiac troponin T (cTnT); high-sensitivity cardiac troponin T (hs-
cTnT); hazard ratio (HR); angiotensin converting enzyme inhibitor/angiotensin receptor  
blocker (ACE/ARB). 
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Adjusted full model: age, sex, comorbidities defined as prior MI, stroke, heart failure, COPD, eGFR 
(continuous variable), diabetes, prior revascularization and ongoing medication with aspirin, statins, 
betablockers, or ACE/ARB. Abbreviations: myocardial infarction (MI), cardiovascular (CV), cardiac 
troponin T (cTnT), high-sensitivity cardiac troponin T (hs-cTnT), hazard ratio (HR), Revascularization 
means percutaneous coronary intervention or coronary artery bypass grafting. * Follow-up for all-cause 
mortality ends 14-12-31. **Follow-up for cardiovascular mortality ends 13-12-31, or on the last date 
when the cause-of-death register is updated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 20. HRs for all-cause mortality, cardiovascular mortality, coronary angiography and 
revascularization during 1 year after the visit to the ED for all patients with chest pain from 2009 to 2013. 
                              Biomarker assay 
                                                       cTnT 
                                                  1 Jan 2009 -  
                                                  7 Dec 2010 
hs-cTnT 
8 Dec 2010 -  
24 April 2012 
hs-cTnT 
25 April 2012 -  
31 Dec 2013 
 
Total, n  
 
12,485 
 
11,222 
 
13,507 
 
All-cause mortality* 
   
HR, 95% CI, Adjusted full model Referent 1.09 (0.95-1.25) 1.22 (1.06-1.39) 
 
CV mortality** 
   
HR, 95% CI, Adjusted full model Referent 1.00 (0.79-1.26) 1.31 (1.04-1.66) 
 
Coronary angiography  
   
HR, 95% CI, Adjusted full model Referent 1.14 (0.99-1.31) 1.13 (0.98-1.31) 
 
Revascularization 
   
HR, 95% CI, Adjusted full model Referent 1.17 (0.98-1.39) 1.19 (1.00-1.43) 
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Discussion 
The transition from conventional cTnT to hs-cTnT was associated with increased 
mortality and more frequent coronary angiography and revascularization. 
 
After the change of faulty batches in 2012, which led to an increased sensitivity of the 
hs-cTnT assay, we noted a decrease in the proportion of patients with a hs-cTnT level 
of <5 ng/L and a parallel increase in the proportion of patients with a hs-cTnT level of 
5-14 ng/L. The proportion of patients with a hs-cTnT >14 ng/L was virtually 
unchanged; this has also been reported in previous studies [83,91].  
 
Several factors were unknown to us and must count as limitations of the study. As 
discussed previously, an elevated hs-cTnT level may originate from conditions other 
than MI, causing the patient to be admitted to the hospital. Additionally, whether any 
advancements ocurred in practice for non-cardiac diagnoses that may have affected the 
long-term mortality of the admitted patients remains unknown. Finally, we had no 
information regarding the decision on whether to admit or discharge a patient, such as 
clinical symptoms. 
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DISCUSSION 
 
METHODOLOGICAL CONSIDERATIONS 
 
Internal validity 
Internal validity refers to the extent to which a test measures what we think it is 
measuring. Epidemiologic studies are subject to several errors, mainly systematic 
errors and random errors, that decrease the accuracy of the study results. 
 
Study design 
Because it is impossible to study complete collections of anything, one must define a 
sample from which to draw conclusions. A study begins by defining a background 
population and choosing an epidemiological study design, usually an interventional 
(such as randomized controlled trial) or observational design. Observational studies 
can be further divided into longitudinal and cross-sectional studies, which in turn 
comprise case-control, cohort, and ecological studies. The present thesis contains 
cohort studies. 
 
In a cohort study, outcomes between an exposed population and non-exposed 
population are compared. If the study is retrospective and based on thorough registries, 
an immediate evaluation of outcomes of diseases or deaths can be performed. 
However, more details concerning patients signs and symptoms can be difficult to 
track because of the retrospective nature of the study. Numerous registries with high 
validity in Sweden facilitate retrospective cohort studies. 
 
Systematic error 
Systematic errors, or bias, arise due to short-comings in the study design and occur 
when measures divert from the true value in a systematic way. Observational studies 
are not randomized with even allocation of subjects to each group. Therefore, it is 
fundamental to consider other explanations that may affect the results, such as 
systematic errors. A systematic error is not dependent on the size of the study 
population; thus it is not possible to increase the number of subjects to avoid 
systematic errors. Different types of bias affect the internal validity of a study. A 
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study with complete absence of systematic errors is considered to have high validity. 
Three types of systematic errors are mainly discussed: selection bias, information bias, 
and confounding bias (or simply confounding) [92]. 
 
 
Selection bias arises when there is a difference between the participants chosen for the 
study and the background population that the study population is thought to represent. 
This type of bias is common in case-control studies, when the probability of being 
selected as a case or control is associated with the exposure status. In retrospective 
cohort studies, selection bias can arise if the study population is not well defined or the 
material from which the cohort was retrospectively defined was incomplete or 
excluded individuals before the beginning of follow-up, possibly because of death or 
emigration [92].  
 
In Studies I to IV, the broad inclusion of unselected patients visiting the ED reduced 
the risk of selection bias with respect to which patients were included in the study. In 
prospective studies, patients in the ED have commonly been selected to participate in 
the study and have thus been found to have a higher risk of MI than unselected real-
world patients. This leads to a non-representative population sample of patients with 
chest pain. For example, in previously reported prospective studies, the incidence of 
prior MI was reportedly 25%; in contrast it was 14% in our retrospectively collected 
cohort [93]. Likewise, the reported rate of prior revascularization is approximately 
30% while it was 14% in our cohort [93]. If any differences were present between the 
retrospectively enrolled patients in our studies, these differences were randomly 
included in both the exposed and non-exposed patient groups. 
A risk of selection bias may have been present in Studies III and IV, because older 
patients with more comorbidities are more likely to be admitted to the hospital for 
observation than fairly healthy patients, who are discharged to a greater extent. 
However, to control for this, we adjusted for differences in characteristics between 
admitted and discharged patients.  
 
 
Information bias occurs when information gathered from or about the study 
participant is incorrect. Studies I to IV relied upon diagnoses previously evaluated to 
have high validity in national registries. The diagnosis of MI was reportedly correct 
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in 98% to 100% of cases [84].  
One example of information bias is misclassification, which occurs when study 
participants are assigned to the wrong category. In Studies I to IV, the troponin 
analysis for each patient was performed in the laboratory, which was blinded to the 
patient´s status.  
The outcome mortality is difficult to misclassify because it is an irreversible state 
and virtually no information concerning death is missing. Although the national 
registries are of high quality, there may have been some patients suffering 
misclassified MIs, leading to bias in our results. 
During Study III, the rate of autopsies was very low. Therefore, subgrouping 
mortality into cardiovascular and non-cardiovascular causes may have been 
associated with misclassification. Misclassification may also have occurred because 
all studies evaluate time periods associated with the low-end shift of hs-cTnT. One 
study revealed that about 8% of patients visiting for chest pain were at risk of 
misdiagnosis [83]. 
Information bias can also be introduced when patients with missing values are 
excluded from a study. In Study II, 122 patients had missing information on eGFR and 
were excluded from the Cox proportional regression models. 
 
 
Confounding bias is another type of systematic error. A confounder is a factor that is 
associated with both the exposure and the outcome. Three conditions must be fulfilled 
for confounding to arise: 1) it is associated with the exposure, 2) it is an independent 
risk factor for the disease, and 3) it is not part of the causal link from exposure to 
outcome (FIGURE 13).  
 
 
 
FIGURE 13. A confounder is associated with the exposure and the outcome, but is not part of the 
causal link. 
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As an example, age can be regarded as a confounder in determining the association 
between physical activity and MI. The distribution of age may differ among subjects in 
the physical activity group. Younger subjects tend to be more physically active and 
have a lower risk of MI. Age is thus associated with both physical activity and MI but 
it is not causally linked to the development of MI. Adjusting for age would allow for a 
fair estimation of the effect between physical activity and MI (FIGURE 14).  
 
 
 
FIGURE 14. Age as a confounder for physical activity and myocardial infarction (MI). 
 
 
Multivariable regression models were used and stratifying analysis were performed to 
reduce confounding in all studies in this thesis. Adjustments were made for the most 
important risk factors, such as age, sex, and comorbidities that may have been 
associated with MI, death, or the investigations performed. Other methods of handling 
confounding during data selection include restriction, matching and randomization, 
(which also resolves the problem of unknown confounders).  
Confounders may still be present, even after stratification; these are known as 
residual confounders. All studies in this thesis may have been influenced by residual 
confounding factors unknown to us.  
 
Random error and precision 
Random error is the result of chance and affects the precision of the estimate. Random 
error is dependent on the sample size; increasing the sample size decreases random 
error and thereby increases precision. Absolute precision is achieved in the absence of 
random error. Case-control studies involve a sampling process, whereas cohort studies 
often do not. 
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Low precision in an epidemiological study may lead to misclassification of individuals 
regarding a disease or exposure, which causes a greater uncertainty in the results. It 
may be more difficult to find true associations; i.e., differences between healthy and 
sick individuals may be difficult to identify even if such differences exist in reality. 
 
Confidence intervals were used in all studies of this thesis, both presenting a range in 
which the true value is likely included and describing the precision of our 
observations. The interval was set at 95%, meaning that there was a 95% likelihood 
that the true value was included within this interval.	The p value can also be used to 
increase precision; this value indicates the probability that the observed value is 
based on chance. A 95% CI and p value of <0.05 are commonly used in medical 
research [92].  
 
 
External validity 
External validity or generalizability is the ability to apply the results of a study to 
another cohort in other countries or settings other than where the study was 
conducted. For Studies I, II and IV, which included both sites of Karolinska 
University Hospital, we believe that the generalizability is high and that the patients 
were representative of ED patients found in countries with a level of health care 
similar as that in Sweden. A limitation in Study III was its single-centre setting. There 
were small differences in characteristics among patients presenting with chest pain to 
each of the two sites at Karolinska University Hospital, which is why we believe that 
the characteristics of the Study III site are similar to those of other EDs in Sweden and 
EDs in other countries with a standard of health care similar to that of Sweden.  
 
 
  
  59 
INTERPRETATION OF FINDINGS 
 
Study I 
 
Single measurement 
The hypothesis of the first study was derived from the clinical experience that patients 
with chest pain and a hs-cTnT level of <5 ng/L who were admitted never seemed to be 
diagnosed with MI. We were aware of few publications before conducting this study  
[5,6,94]. In 2011, one study reported that an undetectable hs-cTnT level seemed to 
have a high NPV and may be suited to rule out MI more safely and rapidly without 
serial testing [5]. Shortly thereafter, another study observed that measuring hs-cTnT at 
presentation and 1 hour later (delta troponin), allowed for both safe rule-in and rule-out 
for MI [94]. The next year, another study compared 4 troponin assays and concluded 
that an undetectable hs-cTnT-level provided a high NPV for MI [6]. These previous 
studies included prospectively recruited patients who were admitted to hospital. In 
comparison, our study was performed on a large unselected cohort of patients in the 
ED independent of risk factors, age, sex, pretest probability, duration of symptoms and 
timing of measurement [5,6]. Several studies have since repeated a similar strategy to 
test a single measurement approach using hs-cTnT [69,95]. 
 
Early measurement of hs-cTnT 
In 11 of the 15 patients with MI, who had a first hs-cTnT level of <5 ng/L and a 
normal ECG, the first hs-cTnT level was measured <2 h after the onset of chest pain. If 
a second hs-cTnT measurement would have been obtained 3 to 4 h after the onset of 
symptoms, it would likely have been elevated. When we measured a second hs-cTnT 
level in admitted patients with an initial concentration of <5 ng/L, an increased hs-
cTnT level was found in only 10% of patients. In addition, 100 medical records were 
randomly screened during the study period to determine the average time to ED arrival 
after chest pain onset. This time was found to be 2.5 hours, which has also been 
reported in previous larger studies [96,97].  
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Mortality 
If some of the patients with a first hs-cTnT level of <5 ng/L who were discharged from 
the ED had instead been admitted to the hospital, they might have had a hs-cTnT level 
of >14 ng/L and thus been diagnosed with MI. When we estimated the risk of death 
within 1 year of the ED visit for patients who were admitted compared with those who 
were discharged, we found no difference in mortality.  
Only two cardiovascular deaths occurred among patients with an undetectable hs-cTnT 
level and a normal ECG during the 1 year of follow-up. This finding shows that an 
undetectable troponin level indicates a low baseline risk for MI and cardiovascular 
mortality and can be used as a prognosticator for long-term mortality. This has also 
been reported previously [74]. 
 
Small elevations of hs-cTnT and PCI 
After the final exclusion, 5 of the remaining 11 patients had a maximum hs-cTnT level 
of <30 ng/L. It is important to determine whether patients with a small elevation in 
their hs-cTnT level would benefit from a diagnosis of MI and the downstream 
investigations and complications that this diagnosis may imply. MI associated with 
PCI has a worse prognosis than PCI without MI [98]. Using the older generations of 
troponin assays, these patients would not have been diagnosed with MI [4]. 
 
Clinical implications 
Chest pain is the second most common reason that patients seek medical attention in 
the ED, and is therefore a considerable global health care burden. Using the results of 
this study, it may be possible to safely discharge a larger proportion of patients with 
chest pain from the ED. Discharging patients instead of admitting them will preserve 
patients´ quality of life and save health care resources. The study results were 
implemented in the ESC 2015 guidelines for diagnostic use of hs-cTnT in the ED [8].  
 
Study II 
 
Admission of patients with a hs-cTnT level of <5 ng/L 
The hypothesis for the second study originated in the aftermath of Study I. A question 
arose regarding whether patients who were discharged home would revisit the ED 
  61 
more often than if they had been admitted to the hospital for observation. We found 
that when healthy patients with chest pain and a hs-cTnT level of <5 ng/L were 
admitted instead of discharged, their risk of revisits to the ED increased, which in turn 
may have contributed to further ED overcrowding. Our results also showed a 
concurrent increased risk of hospital admissions in association with the revisit to the 
ED in these patients.  
Investigating patients with a lower risk for disease may have multiple effects. A 
common conception among clinicians is that patients request admission to hospital 
for additional testing and investigations and that they will be reassured and less 
anxious by finally receiving a normal test result [99]. In contrast, recent studies 
[80,100-102] have revealed increased anxiety and impaired quality of life long-term in 
patients after investigations despite normal results. Hence, when low-risk individuals 
are exposed to admission, non-invasive stress testing, or echocardiographies it may 
lead to anxiety and worry about illness rather than reassurance [80,100,101]. 
Clinicians may be reassured by a normal test result, but many patients may still remain 
uncertain if given a negative or inconclusive test result. Although current guidelines 
recommend non-invasive cardiac imaging to prevent future cardiovascular events, no 
available evidence indicates that non-invasive stress testing in patients with low-risk 
chest pain reduces the future risk of MI or cardiovascular death compared with a more 
conservative approach [8,40,103]. Such investigations may also further increase 
anxiety in patients and reduce their quality of life. 
 
Resource utilization 
Patients who were admitted had a more than three-fold higher risk of undergoing 
coronary angiography and revascularization than did discharged patients. Prior studies 
have shown that low-risk patients with chest pain and no MI do not benefit from 
undergoing coronary angiography or revascularization [104]. There is always a risk of 
adverse complications during investigations, such as potential MI during PCI or 
nosocomial infections related to hospital admission. Therefore, unnecessary 
investigations may harm instead of help patients [40,77]. Performing extensive 
investigations also has consequences for the ED, because of an increased length of 
stay, which contributes to overcrowding, causes delays in testing and investigations, 
and lowers patient satisfaction [75,76]. Additionally, overall resource utilization 
increases with severe economic and health care consequences [78-80]. 
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Admission of patients with a hs-cTnT level of >14 ng/L 
Interestingly, patients with a hs-cTnT level of >14 ng/L who were admitted to hospital, 
had a reduced risk of revisits and readmissions. These patients were older and more 
likely to have diabetes or cardiovascular disease. This finding is consistent with 
previous studies in which elderly patients were reported to benefit from admission to 
hospital for medical optimization [105]. 
 
Clinical implications 
Early discharge from the ED instead of admission to hospital seems to be beneficial in 
patients with chest pain and undetectable hs-cTnT levels. This strategy may avoid 
potentially harmful unnecessary investigations, reduce overcrowding in the ED, and 
sustain patients quality of life. Admitting elderly ill patients appears to prevent future 
revisits to the ED, thus reducing readmissions and preserving health care resources.  
 
 
Study III 
 
Admissions to hospital 
The clinical introduction of high-sensitivity assays, raised concerns among clinicians 
globally that an increased proportion of patients with elevated troponin concentrations 
may lead to increased admission rates [106,107]. Our aim was to evaluate admission 
rates after the introduction of hs-cTnT at our hospital and results showed a 36% 
decrease in admissions during the first 4 years of hs-cTnT use. 
Several recent studies have investigated the impact of the introduction of high-
sensitivity assays into the clinical setting [93,108-110]. Only one study evaluated 
changes in admission rates during the first year after introducing a high-sensitivity 
assay and the admission rates did not decrease a few months after introduction of the 
hs-cTnT assay [108].  
 
Several potential reasons could explain a decrease in admission rates for chest pain, 
such as cut-backs in available hospital beds, new guidelines for the care of patients 
with chest pain, novel research that may affect the way patients with chest pain are 
assessed in the ED, or organizational changes in the ED. We were unable to identify 
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any of these factors as potential explanations for the marked decrease in admissions for 
chest pain in our study other than the introduction of the hs-cTnT assay itself and the 
effect it had on the assessment of patients with chest pain in the ED. Additionally, 
overall hospital admissions and admissions for abdominal pain, the most common 
reason for visiting the ED, remained virtually unchanged. 
 
Mortality  
The primary aim of this study was to report trends in admission rates for chest pain; 
assessment of prognosis was only a secondary aim. Some studies have reported 
contradictory results concerning prognosis during hs-cTnT implementation 
[108,110,111]. In our study, the largest relative increase in discharges was found in 
patients with a hs-cTnT level of >14 ng/L (from 15% to 32%). In parallel, all-cause 
mortality was increased by 51% in 2014 compared with 2011, but for non-
cardiovascular deaths only. When patients were stratified according to their hs-cTnT 
level, only patients with a hs-cTnT level of >14 ng/L had significantly increased 
mortality. Our findings indicate that the observed increased mortality rate may have 
been related to the strong reduction in admissions among patients with a hs-cTnT level 
of >14 ng/L. The safety of discharging such a large proportion of patients with a hs-
cTnT level of >14 ng/L, indicating a high risk of adverse outcomes, is questionable. 
We strongly believe that these patients should be admitted and investigated more 
thoroughly than is commonly done today.  
 
Resource utilization 
Conflicting results have also been reported regarding the effects of the clinical 
introduction of high-sensitivity assays on resource utilization [93,108-110]. These 
conflicting results may be due to differences in study populations because the cohorts 
comprised selected high-risk patients with elevated troponin levels. Our results 
obtained from a cohort of completely unselected patients with chest pain, showed a 
significant increase in coronary angiography, but only a small increase in 
revascularization. The marked decrease in hospital stays for chest pain outweighed 
these findings in terms of resource utilization. Because the increase in coronary 
angiography was not paralleled by a similar increase in revascularization it is likely 
that a large proportion of the additional coronary angiography procedures was normal.  
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Clinical implications 
Our results suggest that the introduction of hs-cTnT has led to markedly decreased 
admission rates for patients with chest pain. It appeared safe to discharge 92% of 
patients with undetectable hs-cTnT levels where no increase in adverse events was 
found. In contrast, our results showed a worse prognosis in patients with a hs-cTnT 
level of >14 ng/L; we strongly believe that these patients should be admitted and more 
thoroughly investigated than what is done today. 
 
 
Study IV 
 
Incidence of MI  
After observing trends in admission rates in Study III, we aimed to evaluate outcomes 
and resource utilization since the use of the hs-cTnT assay commenced. Previous 
reports have shown that the incidence of MI has slightly increased since the 
introduction of hs-cTnT [93,110]. However, we observed a slight decrease in the 
incidence of MI during patients hospital stay, possibly because of inherent variation or 
reluctance among physicians to diagnose patients with MI when exhibiting small 
increases in troponin levels that would have been undetected by the previous troponin 
assays.  
 
 
Mortality    
Several studies have reported outcomes when transitioning from conventional troponin 
assays to high-sensitivity assays in clinical practice and report conflicting results. 
Some studies [108-110,112] reported unchanged prognoses and one study indicated 
increased patient survival [111]. Our results showed a 15% increased risk of all-cause 
mortality in patients tested with hs-cTnT compared with cTnT. However, 
cardiovascular mortality was unchanged. This finding needs to be interpreted 
cautiously because of potential residual confounding, which may have changed the 
association with mortality to non-significant if known. We observed a significant 
reduction in admissions for chest pain in parallel with the increase in mortality. The 
patients admitted were older and had more comorbidities; consequently, they probably 
had a higher risk of death. Despite adjustments for comorbidities, eGFR and ongoing 
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medication in our statistical models, some confounders that we could not account for 
may still have been present and might explain the associations found.  
 
Resource utilization 
Our results also demonstrated an increased use of coronary angiography and 
revascularization during the hs-cTnT period, which has been reported in previous 
studies [109,113] while others observed unchanged practice [93,108,112]. It is 
important to identify the underlying study population characteristics, as it reflects the 
need for coronary angiography and revascularization. Patients admitted to cardiac care 
units undergo coronary angiography more often and have been previously 
revascularized to a greater extent compared with our unselected patient population in 
the ED [114]. 
 
Clinical implications 
This study analysed two large patient cohorts tested with either the conventional cTnT 
or hs-cTnT assay and revealed slightly increased mortality, coronary angiography and 
interventions in the cohort tested with hs-cTnT. However, the results of increased 
mortality must be interpreted cautiously. 
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CONCLUSIONS 
 
 
 
Study I Patients with a hs-cTnT level of <5 ng/L and a normal ECG have a 
minimal risk of MI or death and may be safely discharged from the ED.  
 
Study II When low-risk patients with chest pain and a hs-cTnT level of <5 ng/L 
were admitted to the hospital instead of discharged from the ED, we 
observed increased risk of revisits to the ED, recurrent hospital stays, 
coronary angiography and revascularization.  
 
Study III There was a 36% reduction in admissions for chest pain during the 
first 4 years after the implementation of hs-cTnT. All-cause mortality 
and coronary angiography increased slightly while revascularization 
remained stable. 
 
Study IV After the introduction of hs-cTnT, there was a slight increase in all-
cause mortality, coronary angiography and revascularization. 
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